Clinical Trial Update: Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A [Phase 3]

View source ↗

Summary

Phase 3 study evaluating prophylactic antipyretic treatment in children receiving a booster dose of a pneumococcal conjugate vaccine has completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Streptococcal Infections

Drugs mentioned

• Pneumococcal conjugate vaccine GSK1024850A (Pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED | Results posted: 2019-01-18